NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers. A ...

Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...

The relationship between diabetes and prostate-specific antigen (PSA) levels is complex, with potential implications for prostate cancer screening. This study examined the association between glycemic ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Prostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...

Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort study suggested that a low baseline PSA level in midlife was associated with a ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

This article was reviewed by Darragh O'Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you'll probably become familiar with once you start getting ...